The new products, the Trinity Biotech EU Lyme IgG + VlsE EIA and the EU Lyme IgM EIA are designed for use as screening assays in clinical laboratories. They are qualitative serological tests for the detection of IgG and IgM antibodies to the most prevalent and clinically important Borrelia species in Europe, Borrerlia afzelii, Borrelia garinii, and Borrelia burgdorferi.
The company claims that the addition of VlsE to the product significantly boosts sensitivity of the assay. These new products complete Trinity Biotech’s product offering for Lyme disease in Europe, complementing the existing EU Lyme Western Blot confirmatory assays.
Brendan Farrell, CEO of Trinity Biotech, said: “Trinity now offers both screening and confirmatory assays to all markets, thus reinforcing its number one position for Lyme detection in the world.”